UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Multidisciplinary Approach to Understanding Developmental Dyslexia Within Working-Memory Architecture: Genotypes, Phenotypes, Brain, and Instruction

Developmental neuropsychology, 2008-01, Vol.33 (6), p.707-744

2008

Volltextzugriff (PDF)

Differences between good and poor child writers on fMRI contrasts for writing newly taught and highly practiced letter forms

Reading & writing, 2011-05, Vol.24 (5), p.493-516

2011

Volltextzugriff (PDF)

Functional magnetic resonance imaging sequential-finger movement activation differentiating good and poor writers

Journal of clinical and experimental neuropsychology, 2009-11, Vol.31 (8), p.967-983

2009

Volltextzugriff (PDF)

Functional MRI Activation in Children With and Without Dyslexia During Pseudoword Aural Repeat and Visual Decode: Before and After Treatment

Neuropsychology, 2007-11, Vol.21 (6), p.732-741

2007

Volltextzugriff (PDF)

fMRI Sequential-Finger Movement Activation Differentiating Good and Poor Writers

Journal of clinical and experimental neuropsychology, 2009-04, Vol.31 (8), p.967-983

2009

Volltextzugriff (PDF)

Effects of Nonverbal Problem Solving Treatment on Skills for Externalizing Visual Representation in Upper Elementary Grade Students with and without Dyslexia

Journal of educational computing research, 2006, Vol.34 (4), p.381-404

2006

Volltextzugriff (PDF)

Developmental trajectories of symptom severity and adaptive functioning in an inception cohort of preschool children with autism spectrum disorder

JAMA psychiatry (Chicago, Ill.), 2015-03, Vol.72 (3), p.276

2015

Volltextzugriff (PDF)

Investigating phenotypic heterogeneity in children with autism spectrum disorder: a factor mixture modeling approach

Journal of child psychology and psychiatry, 2013-02, Vol.54 (2), p.206-215

2013

Volltextzugriff (PDF)

Comparison of community-based verbal behavior and pivotal response treatment programs for young children with autism spectrum disorder

Research in autism spectrum disorders, 2013-09, Vol.7 (9), p.1168-1181

2013

Volltextzugriff (PDF)

Detection and population genomics of sea turtle species via noninvasive environmental DNA analysis of nesting beach sand tracks and oceanic water

Molecular ecology resources, 2022-10, Vol.22 (7), p.2471-2493

2022

Volltextzugriff (PDF)

Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

Radiotherapy and oncology, 2021-06, Vol.159, p.241-248

2021

Volltextzugriff (PDF)

5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

Journal of medicinal chemistry, 2011-12, Vol.54 (23), p.8013-8029

2011

Volltextzugriff (PDF)

HEALTH PROMOTING BEHAVIOURS AND LIFESTYLE CHARACTERISTICS OF STUDENTS AT SEVEN UNIVERSITIES IN THE UK

Central European journal of public health, 2011-12, Vol.19 (4), p.197-204

2011

Volltextzugriff (PDF)

Investigating the Measurement Properties of the Social Responsiveness Scale in Preschool Children with Autism Spectrum Disorders

Journal of autism and developmental disorders, 2013-04, Vol.43 (4), p.860-868

2013

Volltextzugriff (PDF)

Phenotypic Overlap Between Core Diagnostic Features and Emotional/Behavioral Problems in Preschool Children with Autism Spectrum Disorder

Journal of autism and developmental disorders, 2011-10, Vol.41 (10), p.1321-1329

2011

Volltextzugriff (PDF)

5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

Journal of medicinal chemistry, 2011-12, Vol.54 (23), p.8013-8029

2011

Volltextzugriff (PDF)

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-(( S)-1-Acetyl-2,3-dihydro-1 H-indol-2-ylmethoxy)-3- tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1 H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor

Bioorganic & medicinal chemistry letters, 2010, Vol.20 (1), p.213-217

2010

Volltextzugriff (PDF)

Feeling healthy? A survey of physical and psychological wellbeing of students from seven universities in the UK

International journal of environmental research and public health, 2011-05, Vol.8 (5), p.1308-1323

2011

Volltextzugriff (PDF)

Factor analysis of the Parenting Stress Index-Short Form with parents of young children with autism spectrum disorders

Autism research, 2011-10, Vol.4 (5), p.336-346

2011

Volltextzugriff (PDF)

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (16), p.4647-4651

2009

Volltextzugriff (PDF)

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Journal of medicinal chemistry, 2009-10, Vol.52 (19), p.5803-5815

2009

Volltextzugriff (PDF)

Does the association between depressive symptomatology and physical activity depend on body image perception? A survey of students from seven universities in the UK

International journal of environmental research and public health, 2011-02, Vol.8 (2), p.281-299

2011

Volltextzugriff (PDF)

Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D 2 receptor antagonist

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (3), p.1036-1040

2011

Volltextzugriff (PDF)

Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D₂ receptor antagonist

Bioorganic & medicinal chemistry letters, 2011-02, Vol.21 (3), p.1036-1040

2011

Volltextzugriff (PDF)

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration

Bioorganic & medicinal chemistry letters, 2010-08, Vol.20 (15), p.4598-4601

2010

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Biological And Medical Sciences
(12)
Female
(11)
Male
(11)
Medical Sciences
(11)
Social Sciences
(11)
Psychology
(10)
Animals
(6)
Preschool Children
(6)
Psychology, Developmental
(6)
Psychology. Psychoanalysis. Psychiatry
(6)
Autism
(5)
Chemistry, Medicinal
(5)
Child, Preschool
(5)
Mice
(5)
Pharmacology & Pharmacy
(5)
Pharmacology. Drug Treatments
(5)
Psychopathology. Psychiatry
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Multidisciplinary Approach to Understanding Developmental Dyslexia Within Working-Memory Architecture: Genotypes, Phenotypes, Brain, and Instruction

Differences between good and poor child writers on fMRI contrasts for writing newly taught and highly practiced letter forms

Functional magnetic resonance imaging sequential-finger movement activation differentiating good and poor writers

Functional MRI Activation in Children With and Without Dyslexia During Pseudoword Aural Repeat and Visual Decode: Before and After Treatment

fMRI Sequential-Finger Movement Activation Differentiating Good and Poor Writers

Effects of Nonverbal Problem Solving Treatment on Skills for Externalizing Visual Representation in Upper Elementary Grade Students with and without Dyslexia

Developmental trajectories of symptom severity and adaptive functioning in an inception cohort of preschool children with autism spectrum disorder

Investigating phenotypic heterogeneity in children with autism spectrum disorder: a factor mixture modeling approach

Comparison of community-based verbal behavior and pivotal response treatment programs for young children with autism spectrum disorder

Detection and population genomics of sea turtle species via noninvasive environmental DNA analysis of nesting beach sand tracks and oceanic water

Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

HEALTH PROMOTING BEHAVIOURS AND LIFESTYLE CHARACTERISTICS OF STUDENTS AT SEVEN UNIVERSITIES IN THE UK

Investigating the Measurement Properties of the Social Responsiveness Scale in Preschool Children with Autism Spectrum Disorders

Phenotypic Overlap Between Core Diagnostic Features and Emotional/Behavioral Problems in Preschool Children with Autism Spectrum Disorder

5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-(( S)-1-Acetyl-2,3-dihydro-1 H-indol-2-ylmethoxy)-3- tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1 H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor

Feeling healthy? A survey of physical and psychological wellbeing of students from seven universities in the UK

Factor analysis of the Parenting Stress Index-Short Form with parents of young children with autism spectrum disorders

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

Does the association between depressive symptomatology and physical activity depend on body image perception? A survey of students from seven universities in the UK

Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D 2 receptor antagonist

Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D₂ receptor antagonist

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)—A potent FLAP inhibitor suitable for topical administration

Suchergebnisse filtern